First human test of new cancer drug combo for Tough-to-Treat lung tumors
NCT ID NCT05879978
First seen Nov 01, 2025 · Last updated Apr 22, 2026 · Updated 24 times
Summary
This early-stage study is testing a new combination of two immunotherapy drugs, obrixtamig and ezabenlimab, for adults with advanced small cell lung cancer or related neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to find the highest dose of the drug combination that patients can safely tolerate. Participants receive the drugs by IV infusion and can continue treatment for up to three years if they benefit and tolerate it well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTR François Baclesse
Caen, 14000, France
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Hôpital Louis Pradel
Bron, 69677, France
-
INS Claudius Regaud IUCT-Oncopole
Toulouse, 31059, France
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
Technische Universität Dresden
Dresden, 01307, Germany
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Universitätsklinikum Frankfurt
Frankfurt, 60590, Germany
Conditions
Explore the condition pages connected to this study.